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Background: Basal-like carcinoma are aggressive breast cancers that frequently carry p53 inactivating mutations,
lack estrogen receptor-a (ERa) and express the cancer stem cell markers CD133 and CD44. These tumors also over-
express Interleukin 6 (IL-6), a pro-inflammatory cytokine that stimulates the growth of breast cancer stem/
progenitor cells.
Results: Here we show that p53 deficiency in breast cancer cells induces a loss of methylation at IL-6 proximal
promoter region, which is maintained by an IL-6 autocrine loop. IL-6 also elicits the loss of methylation at the
CD133 promoter region 1 and of CD44 proximal promoter, enhancing CD133 and CD44 gene transcription. In
parallel, IL-6 induces the methylation of estrogen receptor (ERa) promoter and the loss of ERa mRNA expression.
Finally, IL-6 induces the methylation of IL-6 distal promoter and of CD133 promoter region 2, which harbour
putative repressor regions.
Conclusion: We conclude that IL-6, whose methylation-dependent autocrine loop is triggered by the inactivation
of p53, induces an epigenetic reprogramming that drives breast carcinoma cells towards a basal-like/stem cell-like
gene expression profile.
Background
Basal-like tumors are aggressive estrogen receptor-a
(ERa) negative breast carcinomas that have been identi-
fied due to their peculiar gene expression profile [1-3].
Such tumors display a stem cell-like gene expression
profile, including the over-expression of cancer stem
cells (CSCs) markers, such as CD133 [1,4] and CD44
[5-9]. CD44 and CD133 are also over-expressed in mul-
ticellular spheroids (called mammospheres), derived
from breast cancer tissues and cell lines [10,11]. Mam-
mosphere-forming subpopulation of breast cancer cells
are endowed with highly enhanced tumor-initiating cap-
ability and with resistance to cancer therapy, and are
currently dubbed as breast CSCs [12-14]. Similarly to
basal-like tumors, breast CSCs lack ERa expression
[1-3,15,16]. Basal-like tumors also over-express the pro-
inflammatory cytokine Interleukin-6 (IL-6), a potent
growth factor for breast cancer cells that enhances
mammospheres growth capacity and malignant features
in a paracrine/autocrine fashion [3,5,10].
Basal-like breast cancers carry inactivating mutations
of the tumor suppressor p53 in about 80% of cases
[1-3]. It has been reported that p53 represses the
expression of IL-6 and CD44, via direct promoter bind-
ing [17,18]. p53 exerts various check-point activities,
including the repression of gene transcription through
the methylation of DNA promoters, a mechanism of
epigenetic regulation catalyzed by DNA (cytosine-5)-
methyltransferases at CpG dyads dinucleotides [19-21].
Interestingly, basal-like cells and tissues exhibit a pecu-
liar promoter methylation pattern and over-express
genes involved in genomic DNA and histone methyla-
tion [22-25].
We therefore hypothesized that IL-6, CD44, CD133
and ERa take part to the basal-like gene expression pro-
file throughout the epigenetic modification of their pro-
moter regions.
We show that p53 deficiency induces the loss of
methylation at the IL-6 promoter. This phenomenon
starts an autocrine IL-6 loop that favours the loss of
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well as the gain of methylation at ERa promoter. In par-
allel, the expression of IL-6, CD44 and CD133 is
enhanced, and that of ERa is blunted. Moreover, IL-6
induces the methylation of IL-6 distal promoter and of
CD133 promoter region 2, which contain putative
repressor binding sites.
We conclude that p53 deficiency induces an IL-6
dependent epigenetic reprogramming that drives breast




aIL-6, a monoclonal antibody that blocks the IL-6
receptor/ligand interaction [10], recombinant human
IL-6, 4-hydroxytamoxifen (4OHT, Tamoxifen) and the
demethylathing agent 5-aza-2’-deoxycytidine (5azadC)
were purchased from Sigma (Sigma, St-Louis,
MO, USA).
Cell cultures
MCF-7 cells (carrying wild type p53) were cultured in
RPMI medium supplemented with fetal bovine serum
(FBS 10%), 100 IU/mL penicillin, and 100 μg/mL
streptomycin. MCF-7 cells stably transduced with
pBabe retroviral vector encoding p53 dominant-
negative mini-protein were cultured as previously
described [26,27]. MCF-7 derived mammospheres were
obtained as previously described [4,10,27]. P53 defi-
cient MDA-MB231 breast cancer cell line (carrying
R280K mutation) [5] were cultured in Dulbecco’sm o d -
ified Eagle’s medium (DMEM) supplemented with fetal
bovine serum (FBS 10%), 100 IU/mL penicillin, and
100 μg/mL streptomycin.
RNA extraction and RT-PCR analysis
Total RNA was extracted from cultured cells using the
RNA-extracting reagent TRIzol (Invitrogen) according
to the manufacturer’s instructions.
Reverse transcription reaction was performed in a 20
μlv o l u m ew i t h2μgo ft o t a lR N Au s i n gt h eM - M L V
Reverse Transcriptase, following the manufacturer’s pro-
tocol. Oligo-(dT) 12-18 primers (Invitrogen) were used
for the first strand synthesis. PCR primers (Additional
file 1 Table 1) and reagents were purchased from
Invitrogen.
Transient RNA interference
Double-strand RNA oligonucleotides (siRNA) directed
against p53, IL-6 and ERa mRNA (Stealth validated
RNAi DuoPaks), and appropriate control scrambled
siRNA, were purchased from Invitrogen. siRNAs were
transfected to adherent MCF-7 cells (10
5 cells in a
3-cm
2well) at a concentration of 1 μg/well using Lipo-
fectamine 2000 (Invitrogen).
DNA methylation assay
Methylation specific PCR was performed as previously
described [28]. DNA was extracted with phenol/chloro-
form (Sigma) and Proteinase K (Invitrogen, Carlsbad,
CA, USA) and was bisulphite-modified with EZ-Methy-
lation Gold-Kit (Zymo Research Corporation Orange,
CA U.S.A) according to the manufacturer’s instructions.
Bisulphite modified DNA was amplified with primers
designed using design Methyl Express® Software v1.0
(Applied Biosystems Foster City, CA USA) and Beacon
Designer 3.0 (Premier Biosoft International, Palo Alto
CA USA; Additional file 2 Table 2). PCR primers and
reagents were purchased from Invitrogen. PCR protocols
were performed as follows: pre-denaturation step at 95°
C for 2 min, 35 to 40 cycles of denaturation at 95°C for
30 sec, annealing at the appropriate temperature for 30
sec, extension at 72°C for 1 min; final extension at 72°C
for 7 min. Sequence of genomic DNA promoters are:
IL-6 [GenBank: M18403], CD133 p1 and p2 promoters
[GenBank: ay275524], CD44 [GenBank: M59040], ERa
[GenBank: X03635] (Additional file 3 Figure S1). Search
for transcriptional factor binding sites was performed by
TESS: Transcription Element Search Software on the
WWW, Jonathan Schug and G. Christian Overton,
Technical Report CBIL-TR-1997-1001-v0.0 Computa-
tional Biology and Informatics Laboratory, School of
Medicine University of Pennsylvania, 1997 URL:
http://www.cbil.upenn.edu/tess.
Fluorometry
Amplified fragments were resolved onto a 1.8% agarose
gel with ethidium bromide.
Gels were imaged with FluorSMultiImager (Bio-Rad,
Hercules, CA) using UV excitation and a barrier filter of
520 nm. Emission of amplified bands was analysed with
QuantityOne 4.6.6 software (Bio-Rad) using the same
reading frame. Given values are ratios between the
Unmethylated “U” and Methylated “M” band emissions
of the same fragment. Experimental values were normal-
ized with the U/M ratio of control fragments to which a
value of 1 was assigned.
Luciferase Assay
DNA transfection of MCF-7 cells was performed with
Lipofectamine 2000 (Invitrogen). One day before trans-
fection, the cells were seeded at a density of 1.5 × 10
5
cells/well on 6-well plates and transfected with 1 μgo f
luciferase reporters driven by either p53 responsive ele-
ments (Stratagene, La Jolla, CA USA), or the -2,161 to
-41bp IL6 promoter fragment (kindly provided by W. L.
Farrar, NCI-Frederick Cancer Research and Development
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moter 1 fragment (Kindly provided by K. Tabu, Depart-
ment of Stem Cell Regulation, Medical Research
Institute, Tokyo Medical and Dental University, Japan)
[30]. IL-6 promoter reporter activity was also tested
when co-transfected with 1 μg of IRF-1 or IRF-2
encoding pCAG vectors (kindly provided by T. Tanigu-
chi, Department of Immunology, Graduate School of
Medicine and Faculty of Medicine, University of Tokyo,
Japan).
[31]. Firefly Luciferase was normalized by co-trasfect-
ing 10 ng of Thymidine Kinase Renilla Luciferase repor-
ter (Promega Corporation, Madison Wisconsin USA).
All luciferase assays were performed in triplicates fol-
lowing manufacturer’s instructions (Promega).
Luciferase assay on in vitro methylated
Luciferase reporter
In vitro plasmid DNA methylation was performed as
previously described [30]. Briefly, 4 μg of -1192bp to
+10b CD133 promoter 1 fragment [30] were incubated
with 5 units of SssI (CpG) methylase (Zymo Research
Corporation) for 4 h, per 1 μgo fp l a s m i dD N Ai np r e -
sence (methylated) or absence (unmethylated) of 0.64
mM S-adenosylmethionine. After phenol purification,
equal amounts of methylated and unmethylated reporter
constructs were assessed by digestion with the methyla-
tion-sensitive restriction enzyme HpaII (Promega) and
were then assessed in a luciferase assay as above
described.
Western blot
Protein concentration was determined by Protein Assay
reagent (Bio-Rad, Richmond, CA, USA). Sixty μg of pro-
teins were separated by SDS-PAGE and transferred to a
nitrocellulose filter that was subsequently incubated
with TBS buffer containing 5% dried nonfat-milk for
2 hour at room temperature (RT). Filters were probed
with mouse monoclonal antibodies to p53 (DO-1 Santa
Cruz Biotechnology, Santa Cruz, CA, USA), human
STAT-3 and phosphorylated STAT-3 (Cell Signaling
Technology, Danvers, MA USA) and to b-Actin (Santa
Cruz). Bound antibodies were detected with peroxidase-
labelled goat antibody to mouse or rabbit IgG and
visualized by enhanced chemiluminescence reagents
(Amersham Pharmacia Biotech, Freiburg, Germany).
IL-6 ELISA Assay
Quantitative detection of human IL-6 in cell culture
supernatants was determined by Human IL-6 ELISA kit
(Immunological sciences, Roma, Italy). The assay was
performed in duplicates, following manufacturer’s
instructions. The plate was read by Thermo Labsystems
Multiskan Ascent Photometric plate reader for 96 and
384 well plates (American Instrument Exchange, Inc.,
Haverhill, MA, USA).
Immunofluorescence
Adherent cells (seeded at a density of 5 × 10
4)a n d
mammospheres were fixed with 4% paraformaldehyde
for 10 minutes, permeabilized with Triton X-100 0.2%
for 30 minutes and incubated with anti-CD44 mouse
monoclonal antibody (1:250, Cell Signaling) in PBS-1%
BSA for 1 h at 37°C. After PBS washing, cells and mam-
mospheres were incubated with anti-mouse fluorescein-
conjugated antibody (1:250, Santa Cruz) in PBS-1% BSA
for 45 min at 37°C in dark room and with DAPI solu-
tion (1:1000, 4’,6-diamidino-2-phenylindole, KPL,
G a i t h e r s b u r g ,M DU S A )f o r1 5m i n ,a n dm o u n t e di n
anti-fade Pro long reagent mounting medium (Molecu-
lar Probes Inc, Eugene, Oregon, USA). Images were cap-
tured using a Leica DMI 6000B inverted microscope
(Leica Microsystems GmbH, Wetzlar, Germany).
Statistical analysis
Data were analyzed by t-Student test (SPSS, Chicago, IL,
USA). Data were considered significant when p < 0.05.
Results
Reduced IL-6 proximal promoter methylation and high IL-6
expression in breast cancer cells carrying inactivated p53
In keeping with previous observations [5,31], signifi-
cantly higher IL-6 mRNA and secreted IL-6 protein
levels were found in MDA-MB231 cells (that carry an
R280K inactivating mutation in p53 gene) [5] compared
to p53 wild type MCF-7 cells (Figure 1A). Such a high
IL-6 expression in MDA-MB231 cells was correlated
with the lack of methylation at the -55;+189bp IL-6 pro-
moter region (referred to as IL-6prox, Additional file 3
Figure S1 A). To assess the role of p53 inactivation on
IL-6 expression and IL-6prox methylation, we trans-
duced MCF-7 cells with a retroviral vector encoding a
truncated dominant negative p53 mini-protein [27].
Such cells (named as p53D) disclosed an accumulation
of p53 protein, coupled with reduced p53 activity that
led to a decrease in the mRNA level of p53 responsive
genes (Bnip3, p21Waf1) and to a reduction of p53
dependent luciferase reporter activity (Figure 1C).
According to our hypothesis, p53 D cells showed high
IL-6 mRNA and protein secretion and exhibited a
decrease in IL-6prox methylation compared to empty
vector transfected cells (Figure 1D). As a further proof
o ft h er o l eo fp 5 3i nt h em o d u l a t i o no fI L - 6e x p r e s s i o n
and IL-6prox methylation level, we transfected MCF-7
cells with p53 specific siRNA (sip53) and we found an
increase in IL-6 mRNA level, as well as a reduction of
methylation at IL-6prox (Additional file 4 Figure S2).
These data suggest that p53 inactivation enhances IL-6
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mal promoter region in breast cancer cells.
Decreased methylation at IL-6prox promoter region is
induced and maintained by exogenous or autocrine IL-6
We have previously observed that IL-6 exposure in
breast cancer cells elicits the up-regulation of its own
mRNA [10]. We here confirmed that both the cytokine
itself and 5-AzaCytidine (5azadC) administration elicited
IL-6 expression and a parallel decrease of IL-6prox
methylation (Figure 2A). Accordingly, exposure of
MDA-MB231 and p53 D cells to aIL-6 (an antibody
which blocks IL-6/IL-6 receptor interaction and activity,
Additional file 5 Figure S3) led to a down-regulation of
IL-6 expression, to an increase in methylation at
IL-6prox and to a decrease in IL6 promoter driven-
luciferase activity (IL6P-Luc, Figure 2B). As a support
for the role of IL-6 in the modulation of IL-6prox
Figure 1 p53 inactivation up-regulates IL-6 expression and induces the loss of methylation at IL-6 proximal promoter. a) IL-6 ELISA
assay and RT-PCR analysis of IL-6 mRNA level in MCF-7 and MDA-MB231 cells; b) quantitative evaluation of IL-6prox methylation-specific PCR
analysis (MS-PCR) in MCF-7 and MDA-MB231 cells. “U” stands for Unmethylated and “M” Methylated specific PCR product; c) Western blot
analysis of p53 protein level, RT-PCR analysis of Bnip3 and p21Waf1 mRNA level and luciferase assay of p53 responsive reporter plasmid (p53-
Luc) in MCF-7 cells transduced with empty (pBabe) or p53 mini-protein (p53D) retroviral vector; d) IL-6 ELISA assay, RT-PCR analysis of IL-6 mRNA
level and quantitative evaluation of IL-6prox MS-PCR analysis in pBabe/p53 D cells. b-Actin was assessed as quantitative control for RT-PCR and
Western Blot. Student t test, *p < 0.05,
#p < 0.005. NSF: Non Specific Fragment.
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analysis of IL-6 mRNA level and quantitative evaluation of IL-6prox MS-PCR analysis in MCF-7 cells in presence/absence of IL-6 (10 ng/ml, 48 h)
or 5AzadCytidine (5azadC, 15 μM, 48 h); b) IL-6 ELISA assay, RT-PCR analysis of IL-6 mRNA level, quantitative evaluation of IL-6prox MS-PCR
analysis and IL-6 promoter driven luciferase assay (IL6P-Luc) in MDA-MB231cells and p53 D cells in presence/absence to aIL-6 (1.5 μg/ml, 48 h);
C) IL-6 ELISA assay, RT-PCR analysis of IL-6 mRNA level and quantitative evaluation of IL-6prox MS-PCR analysis in MCF-7 derived mammospheres
(MCF-7S) or MCF-7 adherent cells; b-Actin was assessed as quantitative control for RT-PCR analysis. Student t test, *p < 0.05;
#p < 0.005. n.a.: not
assessed.
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mammospheres (MCF-7S), which express high levels of
IL-6 mRNA and secreted protein show a reduced
methylation at IL-6prox compared to MCF-7 adherent
cells (Figure 2C). Hence, IL-6 elicits its own mRNA
expression and proximal promoter loss of methylation
in breast cancer cells.
Up-regulation of CD133, CD44 and down-regulation of
ERa expression mRNA by IL-6 and 5azadC in breast
cancer cells
We then aimed at investigating whether other genes
involved in the basal-like gene profile are regulated by
IL-6. The administration of IL-6 or 5azadC to MCF-7
cells up-regulated CD133 and CD44 and down-regulated
ERa mRNA levels (Figure 3A).
Moreover, the administration of aIL-6 or an IL-6 spe-
cific siRNA (siIL-6) to p53 D and MDA-MB231 cells
down-regulated CD133 and CD44 mRNA and up-
regulated ERa mRNA expression (Figure 3B). These
data prompted us to test the hypothesis that CD133,
CD44 and ERa may be epigenetically controlled by IL-6.
Decrease in methylation at CD133 proximal promoter by
exogenous or autocrine IL-6
We observed that the administration of IL-6 or 5azadC
reduced the methylation at CD133 promoter 1 (CD133p1,
Additional file 3 Figure S1 B and Figure 4A). Accordingly,
IL-6 triggered the activity of CD133p1 driven luciferase
reporter, which was inhibited by in vitro methylation
(Additional file 6 Figure S4 A). A reduction in methylation
at CD133p1 was then observed in IL-6 expressing MCF-7
S compared to adherent MCF-7 cells (Additional file 6
Figure S4 B). Moreover, a substantial decrease of
CD133p1 methylation was found in p53 D, sip53 trans-
fected (Figure 4B) and MDA-MB231 cells (Additional file
6 Figure S4 C). The administration of aIL-6 or the trans-
fection of siIL-6 induced a gain of methylation of
CD133p1 in p53 D (Figure 4C) and MDA-MB231 cells
(Additional file 6 Figure S4 D). These data suggest that IL-
6 elicits an epigenetic control on CD133p1 promoter.
Reduced methylation at CD44 proximal promoter by
exogenous or autocrine IL-6
We observed that the administration of IL-6 or 5azadC
to MCF-7 cells decreased methylation at CD44 proximal
promoter (CD44p, Additional file 3 Figure S1 C, Figure
5A). Reduced CD44p methylation was also observed in
MCF-7 S compared to adherent MCF-7 cells (Additional
f i l e7F i g u r eS 5A ) .M o r e o v e r ,w ef o u n dar e d u c t i o no f
CD44p methylation in p53 D, sip53 transfected (Figure
5B) and MDA-MB231cells (Additional file 7 Figure S5
B), a phenomenon that was reversed by aIL-6 and siIL-
6 administration (Figure 5C and Additional file 7 Figure
Figure 3 Regulation of CD133, CD44 and ERa mRNA by
exogenous or autocrine IL-6. RT-PCR analysis of CD133, CD44,
ERa mRNA level in: a) MCF-7 cells in presence/absence of IL-6 (10
ng/ml, 48 h) or 5azadC (15 μM, 48 h), b) p53 D cells and MDA-
MB231 cells in presence/absence of aIL-6 (1.5 μg/ml, 48 h) or
transfected with scr/siIL-6 (1 μg, 48 h). b-Actin of panel a) and b)
are reported in panels 2a and 2b, respectively.
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(CD133p1) by exogenous or autocrine IL-6. Quantitative
evaluation of CD133p1 MS-PCR analysis in: a) MCF-7 cells in
presence/absence of IL-6 (10 ng/ml, 48 h) or 5azadC (15 μM, 48 h);
b) pBabe/p53 D and scr/sip53 transfected (1 μg, 48 h) MCF-7 cells,
c) p53 D cells in presence/absence of aIL-6 (1.5 μg/ml, 48 h) or
transfected with scr/siIL-6 (1 μg, 48 h). NSF Non Specific Fragment.
Figure 5 Reduction of methylation at CD44 proximal promoter
(CD44p) by exogenous or autocrine IL-6. Quantitative evaluation
of CD44p MS-PCR analysis in: a) MCF-7 cells in presence/absence of
IL-6 (10 ng/ml, 48 h) or 5azadC (15 μM, 48 h); b) pBabe/p53 D and
scr/sip53 transfected (1 μg, 48 h) cells, c) p53 D cells in presence/
absence of aIL-6 (1.5 μg/ml, 48 h) or transfected with scr/siIL-6 (1
μg, 48 h).
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regulation of CD44 gene.
Increased methylation at ERa promoter by exogenous or
autocrine IL-6
We also found that IL-6 or 5azadC elicited a gain of
methylation at ERa promoter (ERap, Additional file 3
Figure S1 D, Figure 6A). Accordingly, MDA-MB231 and
p53 D exposed to aIL-6 or transfected with siIL-6
showed a decrease of ERap methylation (Figure 6B).
These data suggest that an IL-6 dependent epigenetic
mechanism may take part to ERa down-regulation in
basal-like carcinoma.
Increased methylation at IL-6 distal promoter and at
CD133 promoter region 2 by exogenous or autocrine IL-6
In basal-like cancer, complex changes in genomic DNA
methylation pattern have been reported [22-25]. In this
regard, we found that the administration of IL-6 to
MCF-7 cells elicited an increase of methylation at IL-6
distal promoter (IL-6dist, Additional file 3 Figure S1 E
and Figure 7A). Moreover, aIL-6 administration to p53
D and MDA-MB231 cells reduced methylation at
IL-6dist (Figure 7B). Such region harbours putative con-
sensus binding sites for Interferon regulatory transcrip-
tion factor 1/2 (IRF-1/2, Additional file 3 Figure S1 E)
that can act as repressor for gene transcription [32]. In
this regard, we observed that IL6P-Luc activity was
reduced when co-transfected with vectors encoding IRF-
1/2 proteins (Figure 7C).
We also observed that methylation at CD133 promoter
2 region (Additional file 3 Figure S1 F) was increased
following IL-6 exposure in MCF-7 cells (Figure 8A).
Accordingly, CD133p2 methylation was decreased in
p53 D and MDA-MB231 cells following the administra-
tion of aIL-6 (Figure 8B). Due to the presence of several
putative ERa binding sites at CD133p2 (Additional file 3
Figure S1 F), we hypothesized that ERa exerts a repres-
sive activity on CD133 expression. In line with this
hypothesis, when ERa positive MCF-7 cells were
exposed to the ERa inhibitory drug Tamoxifen or to an
ERa specific siRNA an up-regulation of CD133 mRNA,
paralleled by a substantial gain of methylation at
CD133p2 were observed (Figure 8C).
These data indicate that IL-6 induces complex
changes in genomic DNA, including the methylation of
putative repressor regions.
Discussion
In this investigation, we show that the abrogation of p53
function, a distinctive feature of basal-like breast carci-
nomas, is functionally associated with the loss of methy-
lation at the IL-6 proximal promoter, a crucial region
for IL-6 gene expression [29,31]. In p53 deficient breast
cancer cells, the loss of methylation at IL-6 proximal
promoter is maintained by an autocrine loop which
Figure 6 Gain of ERa promoter (ERap) methylation by autocrine or exogenous IL-6. Quantitative evaluation of ERap MS-PCR analysis in: a)
MCF-7 cells in presence/absence of IL-6 (10 ng/ml, 48 h) or 5azadC (15 μM, 48 h); b) p53 D and MDA-MB231 cells in presence/absence of aIL-6
(1.5 μg/ml, 48 h) or scr/siIL-6 (1 μg, 48 h). PD: Primer Dimers, NSF Non Specific Fragment.
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CD133 and CD44 promoters. These epigenetic modifica-
tions also occur when recombinant IL-6 is exogenously
administered to the cells. In addition, IL-6 administra-
tion elicits the gain of methylation at ERa promoter,
whose epigenetic regulation is of primary importance in
breast cancer biology [1-3,33,34]. Paralleling these phe-
nomena, we observed an up-regulation of CD44 and
CD133 mRNA coupled with a down-regulation of ERa
mRNA. Current literature indicates that the above pat-
tern of gene expression is proper of basal-like tumors
and CSCs [2,3,15,16,27].
Previously, IL-6 itself was found to be over-expressed
in basal-like tumors and CSCs, and to enhance mammo-
sphere forming capacity [10,35]. Accordingly, we report
in the present work that MCF-7 derived mammospheres
show an over-expression of IL-6, CD133 and CD44
genes, as a possible consequence of the loss of promoter
methylation. Considering the close relationship existing
between mammospheres and CSCs [4,10-14], these find-
ings support the very recent observation [35] that IL-6
driven epigenetic changes are associated with CSCs fea-
tures in breast cancer cells. In line with this reasoning,
both CD133 and CD44 have been previously reported to
be regulated by promoter methylation [30,31,36]. More-
over, multiple epigenetic promoter modifications have
been found to control IL-6 gene expression [32,37]. In
fact, basal-like cancer show complex changes in the
genomic DNA methylation pattern [22-25]. Here, we
report that at least two genomic regions located in the
p r o m o t e r so fI L - 6a n dCD133 (IL-6dist, CD133p2 see
Additional file 3 Figure S1 E and F) genes gain methyla-
tion in response to IL-6. In both regions, binding sites
for putative repressors (IRF-1/2 and ERa) are likely to
be present. We therefore we speculate that IL-6 and
CD133 gene transcription can be enhanced by a
Figure 7 IL-6dist gains methylation in response to IL-6 and contains putative repressive IRF-1/IRF-2 binding sites. Quantitative
evaluation of IL-6dist MS-PCR analysis in: a) MCF-7 cells in presence/absence of IL-6 (10 ng/ml, 48 h) or 5azadC (15 μM, 48 h), b) p53 D and
MDA-MB231cells in presence/absence of aIL-6 (1.5 μg/ml, 48 h); c) Luciferase assay of MCF-7 cells transfected with IL6P-Luc in presence/absence
of IL-6 (10 ng/ml), and pIRF-1 or pIRF-2 (1 μg each, 24/48 h) in presence/absence of IL-6 (10 ng/ml, lower panel). Student t test, *p < 0.05;
#p<
0.005.
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regions with opposite functional roles.
As far as protein expression, IL-6 secretion was found
to substantially parallel the changes observed at mRNA
level. Further, we observed that, similarly to what it has
been recently reported [38], CD44 protein was detect-
able in a low percentage of MCF-7 cells and that CD44
expressing cells became more frequent after the admin-
istration of IL-6 for at least 72 hours (Additional file 8
Figure 6S A). Moreover, long term (96 hours) exposure
of MCF-7 cells to IL-6 elicited a substantial increase in
CD44 expressing cells and in the generation of CD44-
expressing mammospheres (Additional file 8 Figure 6S
B). Of interest here is the finding that, despite the strict
regulation of CD133 mRNA by promoter methylation
[30,39], CD133 protein expression was not detected in
our experimental models. This was not a completely
unexpected finding, because recent published observa-
tions on colon CSCs show that CD133 mRNA expres-
sion is present in both CD133 positive and CD133
negative colon cancer cells, and that CD133 protein
undergoes epitope masking during differentiation [40]. It
could be therefore hypothesized that CD133 negative
cells expressing CD133 mRNA represent a “primed”
population, ready to translate the protein under appro-
priate environmental conditions or that CD133 mRNA
itself exerts regulatory functions. Our preliminary data
suggest that CD133 mRNA undergoes cytoplasmic
Figure 8 CD133p2 gains methylation in response to IL-6 and contains putative repressive ERa binding sites. Quantitative evaluation of
CD133p2 MS-PCR analysis in: a) MCF-7 cells in presence/absence of IL-6 or 5azadC (10 ng/ml and 15 μM, 48 h, respectively), b) p53 D and MDA-
MB231 cells in presence/absence of aIL-6 (1.5 μg/ml, 48 h); c) RT-PCR analysis of ERa and CD133 mRNA level and quantitative evaluation of
CD133p2 MS-PCR analysis in MCF-7 cells exposed to Tamoxifen (4OHT, 3 μM, 48 h or vehicle) or to scr or ERa specific siRNA (siERa,1μg, 48 h);
b-Actin was assessed as quantitative control in RT-PCR analysis. PD: primer Dimers.
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Page 10 of 13stabilization to be fully expressed in breast cancer cells
(D’Uva et al., ms in preparation).
Overall, our data suggest that a remodelling of gene
expression toward a basal/stem cell like phenotype may
entail a complex reshaping of promoter methylation
profile, where a loss of and gain of methylation at differ-
ent promoter regions occurs (Additional file 9
Figure S7). The above changes are facilitated by the pre-
sence of functional p53 impairment. Interestingly, loss
of p53 function was recently associated to the shift of
cell division from an asymmetric to a symmetric pattern
in breast cancer stem cells [41]. Such a phenomenon
w a sp r o p o s e da sam a i nm e c h a n i s mf u e l l i n gt u m o r
growth [41]. It could be therefore interesting to investi-
gate whether genes shaping cell division patterns are
part of the epigenetic modifications occurring in basal-
like tumors [22-25].
This study contributes to recent literature supporting
the notion that epigenetic modifications driven by IL-6
are of relevance to determine the gene expression profile
of cancer cells [42,43], and we can conclude that IL-6
blockage holds promises as a potential therapeutic strat-
egy to combat breast cancer.
Additional material
Additional file 1: Table 1. Primers sequence and conditions for RT-PCR.
Additional file 2: Table 2. Primers sequence and conditions for MSP-
PCR.
Additional file 3: Figure S1 Schematic representation of promoter
regions investigated in this study.a )IL-6prox Promoter region; b)
CD133p1 promoter region; c) CD44p promoter region; d) ERap promoter
region; e) IL-6dist promoter region; f) CD133p2 promoter region.
Additional file 4: Figure S2 Reduction of p53 responsive genes
mRNA level, increase of IL-6 expression and loss of IL-6prox
methylation in p53 siRNA-transfected MCF-7 cells. a) RT-PCR analysis
of Bnip3 and p21Waf1 mRNA level in MCF-7 cells transiently transfected
with control (scr) or p53-specific siRNA (sip53, 1 μg, 48 h); b) Western
blot analysis of p53 protein level and RT-PCR analysis of IL-6 mRNA level
in scr/sip53 transfected MCF-7 cells, c) quantitative evaluation of IL-6prox
MS-PCR analysis in scr/sip53 transfected MCF-7 cells; b-Actin was
assessed as quantitative control in RT-PCR and western blot analysis.
Additional file 5: Figure S3 Stat-3 down-regulation by IL-6 blocking
antibody. Western blot analysis of total and phophorylated (P) Stat3
protein level in MCF-7 cells in presence of IL-6 (10 ng/ml 48 h) and p53
D and MDA-MB231 cells exposed to aIL-6 (1.5 μg/ml, 48 h); b-Actin was
assessed as quantitative control for Western Blot analysis.
Additional file 6: Figure S4 CD133p1 methylation reduces promoter
activity, it is reduced in CD133 mRNA expressing MCF-7 S and
MDA-MB231 cells, and it is increased by aIL-6 or siIL-6
administration to MDA-MB231 cells. a) Luciferase assay of CD133p1
reporter (CD133p1-Luc) in presence/absence of IL-6 (10 ng/ml, 24 h) or
in presence/absence of SssI methylase (Methylated/Unmethylated
vector); RT-PCR analysis of CD133 mRNA level and quantitative evaluation
of CD133p1 MS-PCR analysis in: b) MCF-7 S and c) MDA-MB231 cells; d)
quantitative evaluation of CD133p1 MS-PCR analysis in MDA-MB231 cells
in presence/absence of aIL-6 (1.5 μg/ml, 48 h) or transfected with scr/
siIL-6 (1 μg, 48 h); b-Actin was assessed as quantitative control for RT-
PCR analysis. Note that b-Actin of panels b) and c) are reported in Figure
2c and 1a, respectively. Student t test, *p < 0.05;
#p < 0.005. NSF: Non
Specific Fragment.
Additional file 7: Figure S5 CD44p methylation is reduced in CD44
mRNA expressing MCF-7 S and MDA-MB231 cells, and it is
increased by aIL-6 or siIL-6 administration to MDA-MB231 cells. RT-
PCR analysis of CD44 mRNA level and quantitative evaluation of CD44p
MS-PCR analysis in: a) MCF-7S; b) MDA-MB231 cells; quantitative
evaluation of CD44p MS-PCR analysis in MDA-MB231 cells in presence/
absence of aIL-6 (1.5 μg/ml, 48 h) or transfected with scr/siIL-6 (1 μg, 48
h); b-Actin was assessed as quantitative control for RT-PCR analysis. Note
that b-Actin of panels a) and b) are reported in Figure 2c and 1a,
respectively.
Additional file 8: Figure S6 Long term exposure of MCF-7 cells to
IL-6 induces CD44 protein expression and generation of CD44
expressing MCF-7 S. a) Immunofluorescence analysis of CD44
expression (nuclei are counterstained with DAPI) in adherent MCF-7 cells
exposed to 10 ng/ml IL-6 for 72 or 96 h; b) Immunofluorescence analysis
of CD44 expression in MCF-7 S generated from cells cultured in
presence/absence of IL-6 10 ng/ml for 96 h (scale bars: 75 μm).
Additional file 9: Figure S7 Schematic representation of the data. IL-
6 induces a loss of methylation at IL-6prox, CD133p1 and CD44p regions,
concomitant with a gain of promoter methylation at IL-6dist, CD133p2
and ERap (see Additional file 3 Figure 1S for details on the genomic
regions involved). Such changes in promoter methylation pattern
associate with an increase in IL-6, CD133 and CD44 expression, and with
ERa down-regulation. p53 loss of function, by triggering autocrine IL-6
loop, induces the methylation pattern above, that can also be elicited by
exposure to exogenous IL-6.
Abbreviations
NSF: non specific fragment; PD: Primer dimers.
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